Quarterly ResultsCreated 7 August 2026Updated 10 August 20261 min read

Balaxi's Q1 Losses Deepen as Revenue and Profitability Collapse

Balaxi Pharmaceuticals posted a sharp quarterly loss as revenue fell and net profit margin turned deeply negative, continuing a challenging earnings trend.

By HexaWealth Research

Balaxi's Q1 FY27 results show a sharp decline in revenue and a deep plunge into loss, with net profit margin falling to -8%. The company's trailing twelve-month performance offers a stark contrast.

Balaxi Pharmaceuticals' first-quarter results for FY27 reveal a significant deterioration in financial performance. The company swung to a loss as revenue declined both year-on-year and sequentially, highlighting mounting operational challenges.

The latest quarter saw revenue of ₹15.58 crore, down 6.8% from the same period last year and 23% lower than the previous quarter. More critically, profit after tax fell to a loss of ₹1.25 crore, a dramatic 725% decline year-on-year. This pushed the net profit margin deeply into negative territory at -8%, a stark drop from the 1.2% margin in Q1 FY26.

A look at the recent quarterly trajectory shows a clear pattern of weakening profitability.

Revenue (₹ Cr)

Profit (₹ Cr)

Net Profit Margin (%)

Metric	CurrentQ1 FY27	PreviousQ4 FY26	Same quarter LYQ1 FY26
Period	Quarter ended June 2026	Quarter ended March 2026	Quarter ended June 2025
Revenue (₹ Cr)	15.58YoY -6.8%	20.24	16.71
Profit (₹ Cr)	-1.25YoY -725%	0.16	0.20
Net Profit Margin (%)	-8.0YoY -767%	0.8	1.2

This sequential decline contrasts with the company's trailing twelve-month (TTM) performance, which shows a revenue of ₹79.73 crore and a profit of ₹3.7 crore, yielding a net profit margin of 4.6%. The stock's price reflects this difficult period, having fallen 49.2% over the past year.

With a net profit margin now deeply negative and revenue on a downward trend, the immediate focus for Balaxi must be on stabilizing its core operations to halt the erosion of profitability.

Live Chart

· BALAXI

(BSE)

ISIN: INE618N01022

Share or follow HexaWealth

Also read

Want this applied to your portfolio?

Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.

Corporate Address

T-Hub Phase 2, 6th Floor, 20, Inorbit Mall Rd, Vittal Rao Nagar, Madhapur, Hyderabad, Telangana 500081

SEBI Chennai Office: 7th Floor, 756-L, Anna Salai, Chennai - 600002, Tamil Nadu Tel. Board: +91-44- 28880222 / 28526686 Fax : +91-44 -28880333 E-mail : sebisro@sebi.gov.in

Investment in the securities market are subject to market risks. Read all the related documents carefully before investing. Your relationship with the Company will be governed by the Investment Advisory Agreement signed with you and the terms of use of this site. The Investment Adviser shall not incur any liability by reason of any loss, which a client may suffer by reason of any depletion in the value of the assets under advice, which may result by reason of fluctuation in asset value, or by reason of non-performance or under-performance of the securities/funds or any other market conditions.

HexaWealth is a brand name owned and operated by HEXAWEALTH FINANCIAL TECHNOLOGIES PRIVATE LIMITED, a SEBI-registered Investment Adviser (Registration No: INA000019080). Registration granted by SEBI, membership of BASL and certification from NISM in no way guarantee performance or returns. Investments are subject to market risks, read all related documents carefully

In terms of the regulatory requirements, you as a user can either avail our investment advisory services or distribution/facilitation services and not both. The Company shall make all endeavours to ensure segregation of the advisory and distribution activities by not offering both to the same user by placing appropriate post-login disablement/accessibility blocking checks on the website.